Navigation Links
MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
Date:12/11/2007

Three Alternative Five-day Dosing Schedules Appear Similar to Seven-Day in Achieving Red Blood Cell Transfusion Independence, Hematologic Improvement

in All MDS Patients Tested Data Presented at the 49th American Society of Hematology (ASH) Meeting

ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced interim data from a Phase 2 clinical trial evaluating three alternative five-day dosing schedules for Vidaza(R) (azacitidine for injection) that demonstrated safety and response profiles which are consistent with those achieved with the FDA-approved seven-day regimen, as reflected in rates of hematologic improvement (HI) and red blood cell (RBC) transfusion independence. These responses were observed in a broad range of MDS patients, including FAB low-risk patients. These data were presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta.

"The data from this study suggest that a five-day schedule is as effective as the currently approved seven-day schedule at achieving RBC transfusion independence and hematologic improvement in MDS patients," said Dr. Andrew R. Allen, executive vice president and chief medical officer of Pharmion. "A dosing schedule that circumvents the need for weekend dosing would provide a meaningful benefit in terms of convenience to these patients and clinicians."

Roger M. Lyons, MD, FACP, principal investigator of the study at Cancer Care Centers of South Texas and U.S. Oncology Research San Antonio delivered an oral presentation titled "Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza) in Patients with Myelodysplastic Sy
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... Texas , Aug. 20, 2014  Quantum ... five diverse sets of patent families from Bayer Technology ... innovation driver for Bayer AG of Leverkusen, ... patents acquired provide broad intellectual property protection for ... economical high-volume quantum dot (QD) manufacturing. In addition, ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... A survey of U.S. veterans receiving mental health services ... also significant room for improvement among all areas studied. ... 2009, found that patients with a substance use disorder ... health services. Those with substance abuse problems also were ... to them or respected their decisions. , The findings, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 IQ Formulations ... was named to the Inc. 500 , distinguishing it ... United States. IQ Formulations not only made the list, but ... 5,486 percent over the past three years. It also ranked ... state of Florida and the second fastest growing company in ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... News) -- Taking the widely used antibiotic ... heart-related causes, a new study suggests. Because millions ... require urgent confirmation, said the Danish researchers behind the ... small and that guidelines for the use of the ... available. One heart expert wasn,t surprised by the ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Antibiotic Might Raise Heart Risks for Some 2
... most populous city in Australia, with a population of over ... it is also the state capital of New South Wales. ... of the world in energy conservation, in the fight against ... to many areas for an hour. ,Lights were ...
... parties along with activists and film personalities have expressed ... and have vowed to fight it. ,Around ... malnutrition and half of them may die in the ... of Citizen Alliance, who are visiting the villages in ...
... Dana-Farber Cancer Institute have shown in a laboratory study ... counteracts// the damage caused by a form of muscular ... of Genes and Development, the researchers demonstrated that manipulating ... the muscles of mice with Duchenne muscular dystrophy, slowing ...
... at The University of Manchester have discovered that arthritis ... is processed in the //parts of the brain concerned ... Dr Bhavna Kulkarni has captured the first images of ... tomography (PET) scanners based at the Christie Hospital. ...
... till it is six months old could cut the ... ,The Human Immunodeficiency Virus (HIV) is a life-threatening ... to fail. ,Hoosen Coovadia and other researchers ... at the University of KwaZulu-Natal, South Africa, compared solely ...
... pharmaceutical giant, has agreed to stop selling Zelnorm, a ... chances of heart attack and stroke. , ,Officials of ... advised the firm to pull the drug out of the ... its patent application for a cancer drug by Indian authorities. ...
Cached Medicine News:Health News:MPs Vow to Fight Malnutrition in Madhya Pradesh 2Health News:Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice 2Health News:Arthritis Pain Processed in Brain’s 'fear Zone,' First PET Scans Revea 2Health News:Breastfeeding Could Cut HIV Risk to Babies 2Health News:Constipation Drug Linked to Heart Attack Pulled Out 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: